Screener
Dyne Therapeutics, Inc. DYN DYNE-101DM1 — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating Expenses | ||
| Z-rostudirsen (DMD) | $37,747 | $21,093 |
| Z-basivarsen (DM1) | 14,782 | 45,434 |
| Platform and external research and development | 11,465 | 8,235 |
| Personnel related | 28,555 | 20,701 |
| Stock-based compensation | 13,081 | 13,020 |
| Facility-related and other | 11,860 | 6,916 |
| Professional and consulting fees | 7,786 | 6,973 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dyne Therapeutics, Inc.'s DYNE-101DM1 — research and development expense?
- Dyne Therapeutics, Inc. (DYN) reported DYNE-101DM1 — research and development expense of $14.78M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s DYNE-101DM1 — research and development expense changed year-over-year?
- Dyne Therapeutics, Inc.'s DYNE-101DM1 — research and development expense decreased by 67.5% year-over-year, from $45.43M to $14.78M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s DYNE-101DM1 — research and development expense?
- Over 3 years (2022 to 2025), Dyne Therapeutics, Inc.'s DYNE-101DM1 — research and development expense has grown at a 66.7% compound annual growth rate (CAGR), from $31.34M to $145.08M.
- What does DYNE-101DM1 — research and development expense mean?
- This metric represents the total operating costs directly attributable to the research, clinical development, and regulatory advancement of the specific therapeutic candidate targeting Myotonic dystrophy type 1. It captures the investment intensity required to progress the asset through clinical trials, including manufacturing process development and preclinical studies. Monitoring this expenditure provides insight into the company's capital allocation strategy and the pace of development for its core pipeline assets.
Ask your AI about Dyne Therapeutics, Inc.'s dyne-101dm1 — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude